Bio-Techne Corp.

Day range

$72.55 – $72.63

Open

$72.60

Prev close

$72.62

Volume

1.9M

Market cap

$11.39B

Shares out

156.82M

P/E

62.62

P/S

9.37

P/B

5.40

P/FCF

43.26

ROE

8.6%

ROA

7.0%

Debt/Equity

0.09

Div yield

0.44%

As of Oct 22, 2026

• Shareholder meetingsSep 23, 2026

  On September 23, 2026, Bio-Techne Corporation held a special meeting of shareholders to consider and vote on certain proposals related to the Agreement and Plan of Merger. The Merger Agreement Proposal was approved with 121,929,544 votes for, 1,208,817 votes against, and 30,610 votes abstaining.

• Deal agreementsSep 14, 2026

  On June 25, 2026, Bio-Techne Corporation ... entered into an Agreement and Plan of Merger ... providing that ... Merger Sub will merge with and into Bio-Techne ... whereupon Bio-Techne will continue as the surviving corporation and a wholly-owned subsidiary of Merck KGaA, Darmstadt, Germany.

• Earnings and performanceAug 12, 2026

  A copy of the press release issued by Bio-Techne Corporation on August 12, 2026, describing the results of operations for the quarter and year ended June 30, 2026, and its financial condition as of June 30, 2026 is attached hereto as Exhibit 99.1.

• Executive leadershipJun 26, 2026

  On June 23, 2026, in connection with the contemplated Merger, the Compensation Committee of the Board (the "Compensation Committee") approved cash retention bonus awards to each of the Company's current named executive officers pursuant to retention agreements (the "Retention Agreements") in order to encourage the Company's named executive officers to remain with the Company and motivate their continued strong performance until the Effective Time. The Compensation Committee approved the following lump sum cash bonus amounts (the "Retention Bonuses") payable to the Company's named executive officers under the Retention Agreements: Kim Kelderman – $2,120,976; Jim Hippel – $1,541,510; William Geist – $1,161,014; Shane Bohnen – $971,097; and Steve Crouse – $910,263.

• Deal agreementsJun 25, 2026

  Bio-Techne Corporation, a Minnesota corporation ('Bio-Techne'), and Merck KGaA, Darmstadt, Germany, a German corporation with general partners, issued a joint press release announcing the execution of an Agreement and Plan of Merger, by and among Bio-Techne, Merck KGaA, Darmstadt, Germany and EMD Holdings NewCo, Inc., a Minnesota corporation and a wholly-owned subsidiary of Merck KGaA, Darmstadt, Germany.

• TMOThermo Fisher Scientific, Inc.-0.40%
• AAgilent Technologies Inc.-0.47%
• RVTYRevvity, Inc.+0.90%
• MTDMettler-Toledo International-0.85%
• WATWaters Corp-0.42%
• IQVIQVIA Holdings Inc.+0.37%
• CRLCharles River Laboratories International, Inc.+1.68%
• BIOBio-Rad Laboratories, Inc.Class A+1.77%

Days to cover

2.1

Short interest

7.39M

Avg volume

3.56M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• INCY or TECH: Which Is the Better Value Stock Right Now?
  positiveZacks Investment Research· Sep 30, 2026
• Why Is Techne (TECH) Down 0.1% Since Last Earnings Report?
  neutralZacks Investment Research· Sep 11, 2026
• $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger – AUUD, TECH, CZR and CBAN
  neutralGlobeNewswire Inc.· Sep 9, 2026
• Global Multiplex Assays Market 2026 Edition - Consumables Dominate Multiplex Assays with 68% Market Share
  positiveGlobeNewswire Inc.· Sep 4, 2026
• Halper Sadeh LLC is Investigating Whether ACA, TECH, IRDM, LCII are Obtaining Fair Deals for their Shareholders
  negativeGlobeNewswire Inc.· Jul 6, 2026